This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case
by Arpita Dutt
Lilly (LLY) was among the biggest gainers among major pharma stocks last week with the company providing better-than-expected guidance for 2017.
Lilly Stock Surges on Robust 2017 View; Launches Basaglar
by Zacks Equity Research
Eli Lilly and Company (LLY) issued a better-than-expected financial guidance for 2017, alleviating investor concern to a large extent.
J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?
by Zacks Equity Research
On Tuesday, Johnson & Johnson (JNJ) announced that it has ended talks regarding a possible transaction with Swiss biotechnology company, Actelion Ltd. (ALIOF), reportedly for a disagreement over the purchase price.
Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs
by Arpita Dutt
Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.
Novo Nordisk Files Regulatory Application for Semaglutide
by Zacks Equity Research
Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.
Alnylam Reports Positive Data on Fitusiran, Givosiran
by Zacks Equity Research
Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.
Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile
by Zacks Equity Research
Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.
The Zacks Analyst Blog Highlights: UnitedHealth, 21st Century Fox, Sanofi, MasterCard and Barclays
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, 21st Century Fox, Sanofi, MasterCard and Barclays
Celgene vs. Regeneron: Which Stock is a Better Pick?
by Arpita Dutt
Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
Pharma Stock Outlook - July 2015
by Arpita Dutt
Mergers, acquisitions and deals continue to take center-stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions and licensing agreements are concerned, the trend continues this year as well.
Pharma Stock Outlook - July 2015
by Arpita Dutt
Mergers, acquisitions and deals continue to take center-stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions and licensing agreements are concerned, the trend continues this year as well.